Research groups at the University of Fukui and the University of Tsukuba have identified genotypes associated with the responsiveness of "sublingual immunotherapy" to Sugi pollinosis.Patients with this genotype were found to be less responsive to treatment than those without it.This makes it possible to predict the therapeutic effect of sublingual immunotherapy for Sugi pollinosis in advance.
Allergic rhinitis caused by pollen and mite (house dust) antigens affects 2 in 1 Japanese.Sublingual immunotherapy is the only curative treatment, but it is necessary to continuously observe the therapeutic effect for a few years, and 2 to 3% of patients end the treatment without obtaining a satisfactory effect. are doing.Therefore, it has been desired to develop a biomarker that predicts responsiveness at the start of sublingual immunotherapy.
Among the HLA genes (molecules expressed on the leukocyte surface), the research group focused on the cell surface binding pocket "HLA-DPβ1" to which the cedar pollen antigen peptide binds, and responded therapeutically by the HLA genotype that constitutes the binding pocket. I thought that the sex might be different.
This time, we analyzed the treatment responsiveness and HLA genotype of 203 Sugi pollen sublingual immunotherapy patients, and found that patients with the HLADPB1 * 05: 01 genotype had lower treatment responsiveness than those without it. confirm.In other words, in Sugi pollinosis, the three-dimensional structure of HLA-DPβ1, which is an antigen-peptide binding pocket present on the cell surface, was involved in the responsiveness of Sugi pollen sublingual immunotherapy.
This time, we discovered the world's first pharmacogenetic biomarker that can predict the therapeutic effect of sublingual immunotherapy.As a result, we proposed a new pharmacogenetic test for the HLA gene that can be carried out easily and inexpensively.In the future, it is possible to predict the therapeutic effect of sublingual immunotherapy for Sugi pollinosis in advance and provide better medical care to patients.
Paper information:[Allergy] HLA-DPB1 * 05: 01 genotype is associated with poor response to sublingual immunotherapy for Japanese cedar pollinosis